<DOC>
	<DOCNO>NCT00003912</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know chemotherapy regimen effective treat child liver cancer . PURPOSE : Randomized phase III trial study effectiveness cisplatin without doxorubicin effectiveness combine cisplatin , carboplatin , doxorubicin treat child liver cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy cisplatin without doxorubicin term tumor response , complete resection rate , overall survival , event free survival child standard risk hepatoblastoma . - Compare toxicity cisplatin without doxorubicin patient population . - Evaluate whether intensive multiagent regimen include carboplatin , cisplatin , doxorubicin improves response rate chemotherapy subsequent resection rate child high risk hepatoblastoma hepatocellular carcinoma . OUTLINE : This randomize , multicenter study . All hepatoblastoma patient intend treated primary chemotherapy . Hepatoblastoma patient stratify risk ( standard vs high ) . Patients receive cisplatin IV 24 hour day 1 , begin within 15 day diagnosis . Standard risk patient randomize one two treatment arm . High risk hepatoblastoma patient hepatocellular carcinoma patient receive separate multiagent regimen . - Arm I : Patients receive cisplatin IV 24 hour doxorubicin IV 48 hour begin day 15 . Treatment repeat every 21 day maximum 5 course . Tumor response evaluate prior second course . Patients responsive disease receive remain 2 course preoperative phase , undergo delay primary surgery tumor deem resectable , prior receive 2 additional course chemotherapy . Patients whose tumor still unresectable 3 course receive 2 course chemotherapy , undergo surgery feasible . Patients stable disease consider radical surgery salvage chemotherapy . Patients unresectable tumor 5 course may consider liver transplant salvage chemotherapy . - Arm II : Patients receive cisplatin IV 24 hour every 15 day maximum 5 additional course . Tumor response evaluate second course . Patients responsive disease receive another 2 course cisplatin . Patients resectable tumor 4 course undergo delay primary surgery , receive 2 course cisplatin . Patients whose tumor still unresectable 4 course receive 2 course cisplatin , undergo surgery tumor resectable . Patients stable disease may move high risk regimen consider radical surgery . Patients unresectable tumor 6 course may consider liver transplant salvage chemotherapy . Patients high risk hepatoblastoma unresectable hepatocellular carcinoma receive cisplatin IV 24 hour day 29 , 57 , 85 , carboplatin IV 1 hour follow doxorubicin IV 48 hour day 15 , 43 , 71 . Patients responsive resectable disease undergo surgery either day 43 within 3 week day 85 preoperative chemotherapy , receive another 2 course carboplatin doxorubicin day 1 29 post surgery , one course cisplatin day 15 post surgery , total 5 course . Patients responsive unresectable disease day 85 also receive 2 course carboplatin doxorubicin alternate 1 course cisplatin . Definitive surgery re-considered course chemotherapy . Patients stable disease day 43 tumor remain unresectable completion chemotherapy may consider liver transplant . Patients resectable hepatocellular carcinoma primary surgery follow alternate course cisplatin , carboplatin doxorubicin total 4 course cisplatin 3 course carboplatin doxorubicin . Patients follow every 2-3 month 2 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 170-260 patient ( 85-130 patient per treatment arm ) accrue study 5.5 year .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven hepatoblastoma hepatocellular carcinoma Diagnostic surgical biopsy strongly recommend patient mandatory follow : Children 6 month age Children 3 year age Patients normal serum alfafetoprotein ( alfaFP ) Compatible image raise serum alfaFP level mandatory biopsy perform Standard risk disease : Tumors involve 3 hepatic section No extrahepatic abdominal disease No metastases High risk disease : Tumors involve 4 hepatic section AND/OR Evidence extrahepatic metastasis abdominal disease Presence absence metastatic disease must document chest xray and/or lung CT scan PATIENT CHARACTERISTICS : Age : 16 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>stage I childhood liver cancer</keyword>
	<keyword>stage II childhood liver cancer</keyword>
	<keyword>stage III childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>childhood hepatocellular carcinoma</keyword>
</DOC>